The company hopes to push the rare-disease treatment toward FDA approval next year. Four months after ditching its lead drug, ...

Researchers from Pretzel Therapeutics Inc. and the University of Gothenburg have published new insights on how mutations in the POLG gene affect its functionality and are tied to PolG diseases. They ...

The Boston-based company said its gene-editing treatment for people with high cholesterol was well-tolerated with no serious ...

Knife River Corporation , an aggregates-led, vertically integrated construction materials and contracting services company, will host its first quarter 2025 earnings conference call at 11 a.m. EDT ...

TELUS Digital will release its first quarter 2025 results on May 9, 2025, before the North American market open hours, and host a conference call on the same day at 10:00 a.m. (ET) / 7:00 a.m. (PT), ...

Red Ember Recruitment is seeking a detail-oriented and results-driven Commercial Analyst to join our client’s dynamic team in Kempton Park, Gauteng. The ideal candidate will play a critical role in ...

Red Ember Recruitment is seeking a detail-oriented and results-driven Commercial Analyst to join our client’s dynamic team in Kempton Park, Gauteng. The ideal candidate will play a critical role in ...

Wall Street analysts said the results for Verve’s therapy appeared competitive on efficacy, while avoiding any major safety ...

Sage Therapeutics faces challenges with a 90% value drop but shows promise with Zurzuvae for postpartum depression. Click ...

WATERTOWN, Mass., April 09, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader ...

Biogen's $7.22 per share buyout offer signals confidence in Sage's commercial potential and drug pipeline. Read why SAGE ...

Biogen's research organization recently went through an overhaul that company leaders say should allow the Cambridge drugmaker to increase the number of molecules that get into the clinic, and then, ...